Completed
PHASE1
INTERVENTIONAL
NCT06207877
A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This research study tests if CagriSema influences food intake, appetite and emptying of the stomach in people with excess body weight. Participant will either get CagriSema (active medicine) or placebo (a dummy medicine), which has no effect on the body. The treatment participants get is decided by chance. The study will last for about 32 weeks.
Interventions
Name:
Cagrilintide
Type:
DRUG
Description:
Cagrilintide will be administered subcutaneously.
Name:
Semaglutide
Type:
DRUG
Description:
Semaglutide will be administered subcutaneously.
Name:
Placebo
Type:
DRUG
Description:
Placebo will be administered subcutaneously.
Primary Outcomes
Measure:
Relative change in energy intake during ad libitum lunch, evening meal and snackbox
TimeFrame:
Baseline to Day 156
Description:
Measured in percentage (%).
Trial Information
NCT ID
NCT06207877
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE1
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025